Related references
Note: Only part of the references are listed.FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease
Alba Di Pardo et al.
HUMAN MOLECULAR GENETICS (2014)
Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions
C. Brana et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2014)
Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model
Daniel C. Anthony et al.
NEUROPHARMACOLOGY (2014)
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
Adam J. Pawson et al.
NUCLEIC ACIDS RESEARCH (2014)
Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: Comparison with Memantine
Fatemeh Hemmati et al.
BEHAVIOURAL BRAIN RESEARCH (2013)
Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination
Thomas Skripuletz et al.
BRAIN (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: ENZYMES
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: G PROTEIN-COUPLED RECEPTORS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Systematic Review and Meta-Analysis of the Efficacy of Sphingosine-1-Phosphate (S1P) Receptor Agonist FTY720 (Fingolimod) in Animal Models of Stroke
Junfeng Liu et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2013)
Late motor decline after accomplished remyelination: Impact for progressive multiple sclerosis
Natalia Manrique-Hoyos et al.
ANNALS OF NEUROLOGY (2012)
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis
Ernst-Wilhelm Radue et al.
ARCHIVES OF NEUROLOGY (2012)
Endogeneous Remyelination: Findings in Human Studies
Markus Kipp et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2012)
Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions
Tim Clarner et al.
GLIA (2012)
Inflammatory Response and Chemokine Expression in the White Matter Corpus Callosum and Gray Matter Cortex Region During Cuprizone-Induced Demyelination
J. P. Buschmann et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2012)
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
Virginia Devonshire et al.
LANCET NEUROLOGY (2012)
FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination
M. Kipp et al.
MULTIPLE SCLEROSIS JOURNAL (2012)
Fibroblast growth factor 1 (FGFR1) modulation regulates repair capacity of oligodendrocyte progenitor cells following chronic demyelination
Yong-Xing Zhou et al.
NEUROBIOLOGY OF DISEASE (2012)
Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome
Ruben Deogracias et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
BLBP-expression in astrocytes during experimental demyelination and in human multiple sclerosis lesions
M. Kipp et al.
BRAIN BEHAVIOR AND IMMUNITY (2011)
Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model
Hye Jung Kim et al.
FASEB JOURNAL (2011)
Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo
Yinghui Hu et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2011)
Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis
Sarah Al-Izki et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
Ivana Nikic et al.
NATURE MEDICINE (2011)
Sphingosine Kinase 1 and Sphingosine 1-Phosphate Receptor 3 Are Functionally Upregulated on Astrocytes under Pro-Inflammatory Conditions
Iris Fischer et al.
PLOS ONE (2011)
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation
Ji Woong Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices
Veronique E. Miron et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
ADAM12 is expressed by astrocytes during experimental demyelination
Fabian Baertling et al.
BRAIN RESEARCH (2010)
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
J. C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
FTY720 Ameliorates MOG-Induced Experimental Autoimmune Encephalomyelitis by Suppressing Both Cellular and Humoral Immune Responses
Dimitrios Papadopoulos et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2010)
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Volker Brinkmann et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Fingolimod is a potential novel therapy for multiple sclerosis
Orhan Aktas et al.
NATURE REVIEWS NEUROLOGY (2010)
Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis
Alina Kulakowska et al.
NEUROSCIENCE LETTERS (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Activation of Sphingosine 1-Phosphate Receptor-1 by FTY720 Is Neuroprotective After Ischemic Stroke in Rats
Yu Hasegawa et al.
STROKE (2010)
The cuprizone animal model: new insights into an old story
Markus Kipp et al.
ACTA NEUROPATHOLOGICA (2009)
17β-Estradiol and Progesterone Prevent Cuprizone Provoked Demyelination of Corpus Callosum in Male Mice
Peter Acs et al.
GLIA (2009)
FTY720 Reduces Inflammation and Promotes Functional Recovery after Spinal Cord Injury
Kangmin D. Lee et al.
JOURNAL OF NEUROTRAUMA (2009)
Gray matter pathology in (chronic) MS: Modern views on an early observation
Jeroen J. G. Geurts et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination
Maren Lindner et al.
NEUROSCIENCE LETTERS (2009)
Extensive remyelination of the CNS leads to functional recovery
I. D. Duncan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod
Veronique E. Miron et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent
Thomas Skripuletz et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
FTY720 modulates human oligodendrocyte progenitor process extension and survival
Veronique E. Miron et al.
ANNALS OF NEUROLOGY (2008)
A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis
David Wheeler et al.
BRAIN (2008)
Remyelination protects axons from demyelination-associated axon degeneration
K. A. Irvine et al.
BRAIN (2008)
Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease
Yun-Ping Wu et al.
HUMAN MOLECULAR GENETICS (2008)
Grey matter pathology in multiple sclerosis
Jeroen J. G. Geurts et al.
LANCET NEUROLOGY (2008)
Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: Implications for multiple sclerosis
Eva Herrero-Herranz et al.
NEUROBIOLOGY OF DISEASE (2008)
Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells
C. G. Jung et al.
GLIA (2007)
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis
Carolyn A. Foster et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors
Rochelle P. Coelho et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3
Diana Mechtcheriakova et al.
FEBS LETTERS (2007)
Essential roles of sphingosine 1-phosphate/S1P(1) receptor axis in the migration of neural stem cells toward a site of spinal cord injury
Atsushi Kimura et al.
STEM CELLS (2007)
T-cell-mediated disruption of the neuronal microtubule network - Correlation with early reversible axonal dysfunction in acute experimental autoimmune encephalomyelitis
Leah P. Shriver et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Edg8/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival
C Jaillard et al.
JOURNAL OF NEUROSCIENCE (2005)
Amelioration of experimental autoimmune encephalomyelitis in lewis rats by FTY720 treatment
M Fujino et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time
T Kuhlmann et al.
BRAIN (2002)
The immune modulator FTY720 targets sphingosine 1-phosphate receptors
V Brinkmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists
S Mandala et al.
SCIENCE (2002)
Multiple sclerosis and chronic autoimmune encephalomyelitis -: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions
B Kornek et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Acute axonal injury in multiple sclerosis -: Correlation with demyelination and inflammation
A Bitsch et al.
BRAIN (2000)
Share Paper
